Moderna Inc. MRNA, -2.01% said Monday that the Food and Drug Administration granted the company’s experimental respiratory syncytial virus vaccine a Breakthrough Therapy Designation. Moderna said it plans to apply for approval in the first half of this year. The company’s stock has gained 18.7% over the past year, while the S&P 500 SPX, +0.25% is down 4.3%.
This article was originally published by Marketwatch.com. Read the original article here.
